The Incidence Mortality and Survival of Malignant Hematopoietic Neoplasms in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2000-2022 Database Analysis
Author(s)
Vlad Zah, DPhil, Filip Stanicic, PhD (c), Dimitrije Grbic, PhD (c).
ZRx Outcomes Research, Inc., Mississauga, ON, Canada.
ZRx Outcomes Research, Inc., Mississauga, ON, Canada.
Presentation Documents
OBJECTIVES: Analyzing the disease burden of hematopoietic neoplasms (HN) in the US using the Surveillance, Epidemiology, and End Results (SEER) data (released April 2025).
METHODS: Data from 17 US cancer registries (2000-2022) were gathered and analyzed with SEER*Stat. The study population involved malignant HN patients. Outcomes included crude incidence and mortality rates (per 100,000 population) and survival rates (as percentages).
RESULTS: There were 970,230 HN patients, mostly with B-cell neoplasms (59.2%). Patients were mostly 65+ years old (56.9%), males (55.4%), non-Hispanic Whites (70.6%), married (51.6%), metropolitan county residents (87.9%), and had annual household income (AHI) of $65,000-$90,000 (47.0%). Total HN incidence rate was 51.1, with B-cell neoplasms as the most common subtype (30.3). Higher rates were reported among elderly (225.4), males (57.2), non-Hispanic Whites (66.4), non-metropolitan county residents (60.1), and <$40,000 AHI group (56.8). The annual percent change (APC) for HN incidence from 2000-2022 shows an increasing trend (1.2, p<0.05). The same trend was observed for all subgroups, except Hodgkin‘s lymphoma (APC -0.7, p<0.05). Total HN mortality rate was 28.0. The highest rates were reported for B-cell neoplasms (16.4), elderly (172.6), males (32.1), non-Hispanic Whites (38.1), non-metropolitan county residents (36.2), and <$40,000 AHI (36.8). An increasing HN mortality trend was observed (APC 4.0, p<0.05) and for all subtypes, except for precursor lymphoid neoplasms. 5-year HN survival was 58.7%. The lowest 5-year survival rates were observed for acute myeloid leukemias (26.2%), 90+ years (10.3%), males (57.4%), non-Hispanic Blacks (56.3%), widowed (34.5%), non-metropolitan residents (54.0%), and <$40,000 AHI (50.1%).
CONCLUSIONS: The study findings showed a high HN burden. Most HN subtypes demonstrated increasing incidence and mortality trends. The lowest 5-year survival was observed for acute myeloid leukemias, with survival chances of approximately 1 in 4 patients. These results should be a compelling reason to accelerate the discovery and approval of new treatments.
METHODS: Data from 17 US cancer registries (2000-2022) were gathered and analyzed with SEER*Stat. The study population involved malignant HN patients. Outcomes included crude incidence and mortality rates (per 100,000 population) and survival rates (as percentages).
RESULTS: There were 970,230 HN patients, mostly with B-cell neoplasms (59.2%). Patients were mostly 65+ years old (56.9%), males (55.4%), non-Hispanic Whites (70.6%), married (51.6%), metropolitan county residents (87.9%), and had annual household income (AHI) of $65,000-$90,000 (47.0%). Total HN incidence rate was 51.1, with B-cell neoplasms as the most common subtype (30.3). Higher rates were reported among elderly (225.4), males (57.2), non-Hispanic Whites (66.4), non-metropolitan county residents (60.1), and <$40,000 AHI group (56.8). The annual percent change (APC) for HN incidence from 2000-2022 shows an increasing trend (1.2, p<0.05). The same trend was observed for all subgroups, except Hodgkin‘s lymphoma (APC -0.7, p<0.05). Total HN mortality rate was 28.0. The highest rates were reported for B-cell neoplasms (16.4), elderly (172.6), males (32.1), non-Hispanic Whites (38.1), non-metropolitan county residents (36.2), and <$40,000 AHI (36.8). An increasing HN mortality trend was observed (APC 4.0, p<0.05) and for all subtypes, except for precursor lymphoid neoplasms. 5-year HN survival was 58.7%. The lowest 5-year survival rates were observed for acute myeloid leukemias (26.2%), 90+ years (10.3%), males (57.4%), non-Hispanic Blacks (56.3%), widowed (34.5%), non-metropolitan residents (54.0%), and <$40,000 AHI (50.1%).
CONCLUSIONS: The study findings showed a high HN burden. Most HN subtypes demonstrated increasing incidence and mortality trends. The lowest 5-year survival was observed for acute myeloid leukemias, with survival chances of approximately 1 in 4 patients. These results should be a compelling reason to accelerate the discovery and approval of new treatments.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH246
Topic
Epidemiology & Public Health, Real World Data & Information Systems
Disease
Oncology